Treatment with dupilumab leads to sustained improvements in COPD patients with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.

Related Keywords

Germany ,Washington ,United States ,American ,Lily Ramsey ,Surya Bhatt ,Klaus Rabe ,University Of Kiel ,American Thoracic Society ,Marnixe Heersink School Of Medicine ,International Conference ,World Health Organization ,New England Journal ,Birmingham Department ,Medicine Division ,Critical Care Medicine ,Lungen Clinic ,